On July 2, 2020, J&J (Janssen), then part of the Operation Warp Speed, entered into an agreement with Emergent BioSolutions for the manufacture of its viral vector-based COVID-19 vaccine.
However, Emergent was found to have numerous quality issues at its Bayview, Maryland facility culminating